68Ga标记的微胃泌素类似物DOTA-MGS5在晚期甲状腺髓样癌及其他神经内分泌肿瘤患者中的安全性、生物分布与辐射剂量学
这项前瞻性I/IIA期先导研究在本中心纳入6例晚期甲状腺髓样癌(MTC)和6例胃肠胰及支气管肺神经内分泌肿瘤(NET)患者,单次给予180 MBq 68Ga-DOTA-MGS5。给药耐受良好,仅3例出现轻微药物不良反应;示踪剂主要经肾脏排泄,膀胱壁、胃壁和肾脏吸收剂量最高,有效剂量为0.023 ± 0.007 mSv/MBq。
要点
- 68Ga-DOTA-MGS5给药耐受良好,12例中仅3例出现轻微药物不良反应
- 有效剂量为0.023 ± 0.007 mSv/MBq,最高吸收剂量见于膀胱壁、胃壁和肾脏
- 注射后1 h和2 h为PET/CT显像的最佳时间窗
核心结论
- 在I期部分中,除证实给药安全性外,68Ga-DOTA-MGS5显示出可接受的有效全身剂量、总体良好的生物分布以及胆囊收缩素-2受体(CCK2R)显像的可行性。
研究设计与样本
- 前瞻性I/IIA期先导研究(clinicaltrials.gov NCT06155994),在本中心开展,纳入6例晚期甲状腺髓样癌(MTC)和6例经其他PET示踪剂PET/CT证实的胃肠胰及支气管肺神经内分泌肿瘤(NET)患者。
- 所有患者单次接受180 MBq 68Ga-DOTA-MGS5,首批入组的6例纳入剂量学评估,全部12例评估安全性;注射后不同时间点行PET/CT以进行剂量学计算并确定最佳显像时间窗,同时采集血、尿样本进行药代动力学评估。
主要发现
- 给药耐受良好,仅3例患者出现轻微药物不良反应。
- 68Ga-DOTA-MGS5自血液中快速清除,注射后215 ± 10 min时血液中存留的注射活度小于21%。
- 示踪剂主要经肾脏排泄,注射后3 h累积尿排泄大于40%;血浆中证实存在高比例完整放射性肽。
- 最高吸收剂量见于膀胱壁、胃壁和肾脏,有效剂量为0.023 ± 0.007 mSv/MBq。
- 注射后1 h和2 h为PET/CT显像的最佳时间点;在纳入剂量学评估的6例中,2例晚期MTC患者确认局部转移,而4例胃肠胰NET患者中仅1例68Ga-DOTA-MGS5 PET/CT为阳性。
关键数值与推荐
- 单次给药剂量为180 MBq 68Ga-DOTA-MGS5。
- 有效剂量为0.023 ± 0.007 mSv/MBq。
- 注射后215 ± 10 min血液中存留的注射活度小于21%。
- 注射后3 h累积尿排泄大于40%。
- 最佳PET/CT显像时间点为注射后1 h和2 h。
临床怎么用
- 作者报告在I期部分中68Ga-DOTA-MGS5给药安全、有效全身剂量可接受、生物分布总体良好,并显示CCK2R显像的可行性。
- 作者报告注射后1 h和2 h为PET/CT显像的最佳时间窗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the 68Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 (68Ga-DOTA-MGS5). Methods: Six patients with advanced MTC and 6 patients with gastroenteropancreatic and bronchopulmonary NETs confirmed by previous PET/CT imaging with other PET tracers received a single dose of 180 MBq of 68Ga-DOTA-MGS5. The first 6 patients enrolled in the study were included in the dosimetry evaluation, and safety was assessed in all 12 patients. PET/CT imaging was performed at different time points after injection to perform dosimetric calculations and to determine the optimal imaging time window. In addition, blood and urine samples were collected for pharmacokinetic assessments. Results: The administration of 68Ga-DOTA-MGS5 was well tolerated, with minor adverse drug reactions occurring only in 3 patients. 68Ga-DOTA-MGS5 was cleared rapidly from the blood, with less than 21% of the injected activity present in blood 215 ± 10 min after injection. Tracer elimination occurred mainly through the kidneys, with a cumulative urinary excretion greater than 40% 3 h after injection. A high percentage of intact radiopeptide was confirmed in plasma. The highest absorbed dose was found for the urinary bladder wall, the stomach wall, and the kidneys, with an effective dose of 0.023 ± 0.007 mSv/MBq. The time points of 1 and 2 h after injection proved to be optimal for PET/CT imaging. In the 6 patients included in the dosimetry evaluation, local metastasis was confirmed in 2 patients with advanced MTC, whereas only 1 of 4 patients with gastroenteropancreatic NETs was positive in 68Ga-DOTA-MGS5 PET/CT. Conclusion: Besides confirming the safety of administration, within the phase I part of the prospective clinical trial, an acceptable effective whole-body dose, an overall favorable biodistribution, and the feasibility of cholecystokinin-2 receptor imaging could be shown for 68Ga-DOTA-MGS5.
引用
- von Guggenberg E, di Santo G, Uprimny C, et al. Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. J Nucl Med. 2025. PMID: 39819687. doi:10.2967/jnumed.124.268877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。